Differences between Brand Name Drugs and Generic Drugs

Brand Name Drugs vs. Generic Drugs

A brand name drug is a medication marketed by a pharmaceutical company under a specific, proprietary name. When a company develops a new drug, it typically receives a patent that grants exclusive rights to sell the medication for a designated period, often 20 years from the date of filing. During this time, the manufacturer conducts extensive clinical trials to prove the drug's safety and efficacy for its intended use. Once the patent and any other exclusivity periods expire, other manufacturers can apply to the Food and Drug Administration (FDA) or similar regulatory bodies to sell a generic version of the medication.

Generic drugs are pharmaceutical products designed to be the same as an already marketed brand-name drug in dosage form, safety, strength, route of administration, quality, and performance characteristics. The primary legal framework for generic drugs in the United States was established by the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act. This legislation simplified the approval process for generics by requiring an Abbreviated New Drug Application (ANDA) rather than a full New Drug Application (NDA).

Comparison Table

Category	Brand Name Drugs	Generic Drugs
Active Ingredient	Original formulation	Identical to the brand name
Inactive Ingredients	Specified by the developer	May differ (dyes, fillers, preservatives)
Appearance	Distinctive color, shape, and packaging	Must look different due to trademark laws
Research and Development	Requires original clinical trials	Requires bioequivalence studies
Price	Generally higher to recover R&D costs	Generally 80% to 85% lower
FDA Approval Path	New Drug Application (NDA)	Abbreviated New Drug Application (ANDA)
Manufacturing Standards	Must meet CGMP regulations	Must meet CGMP regulations

Venn diagram comparing Differences between Brand Name Drugs and Generic Drugs

Bioequivalence and Standards

The FDA requires generic drugs to demonstrate "bioequivalence" to the brand-name product. This means that the generic manufacturer must prove that the drug delivers the same amount of active ingredient into a patient's bloodstream over the same amount of time. Scientists measure the rate and extent of absorption through two primary metrics: the maximum concentration of the drug (Cmax) and the total area under the plasma concentration-time curve (AUC). Regulatory standards allow for small, statistically insignificant variations in these measurements, similar to the variations found between different batches of the same brand-name drug.

While the active ingredient must be the same, generic drugs often contain different inactive ingredients, also known as excipients. These substances include binders, flavorings, and coatings. While these components do not affect the therapeutic action of the drug, they can occasionally cause different reactions in patients with specific allergies or sensitivities.

Economic Impact

The introduction of generic drugs increases competition in the pharmaceutical market. Because generic manufacturers do not have to repeat the costly animal and clinical (human) studies required for new drugs, they can sell the product at a lower cost. According to the FDA, the presence of multiple generic competitors for a single product can drive the price down to a small fraction of the original brand-name price. In the United States, generic drugs account for approximately 90% of all prescriptions filled, but they represent only a small portion of total drug spending.